Literature DB >> 23918367

Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth.

Xiaojuan Yang1, Yin Zhang, Yunlong Yang, Sharon Lim, Ziquan Cao, Janusz Rak, Yihai Cao.   

Abstract

Placental growth factor (PlGF) remodels tumor vasculatures toward a normalized phenotype, which affects tumor growth, invasion and drug responses. However, the coordinative and spatiotemporal relation between PlGF and VEGF in modulation of tumor angiogenesis and vascular remodeling is less understood. Here we report that PlGF positively and negatively modulate tumor growth, angiogenesis, and vascular remodeling through a VEGF-dependent mechanism. In two independent tumor models, we show that PlGF inhibited tumor growth and angiogenesis and displayed a marked vascular remodeling effect, leading to normalized microvessels with infrequent vascular branches and increased perivascular cell coverage. Surprisingly, elimination of VEGF gene (i.e., VEGF-null) in PlGF-expressing tumors resulted in (i) accelerated tumor growth rates and angiogenesis and (ii) complete attenuation of PlGF-induced vascular normalization. Thus, PlGF positively and negatively modulates tumor growth, angiogenesis, and vascular remodeling through VEGF-dependent spatiotemporal mechanisms. Our data uncover molecular mechanisms underlying the complex interplay between PlGF and VEGF in modulation of tumor growth and angiogenesis, and have conceptual implication for antiangiogenic cancer therapy.

Entities:  

Keywords:  VEGF receptor signaling; antiangiogenic therapy; neovascularization

Mesh:

Substances:

Year:  2013        PMID: 23918367      PMCID: PMC3752238          DOI: 10.1073/pnas.1309629110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

Review 1.  Tumor angiogenesis.

Authors:  Robert S Kerbel
Journal:  N Engl J Med       Date:  2008-05-08       Impact factor: 91.245

2.  PlGF blockade does not inhibit angiogenesis during primary tumor growth.

Authors:  Carlos Bais; Xiumin Wu; Jenny Yao; Suya Yang; Yongping Crawford; Krista McCutcheon; Christine Tan; Ganesh Kolumam; Jean-Michel Vernes; Jeffrey Eastham-Anderson; Peter Haughney; Marcin Kowanetz; Thijs Hagenbeek; Ian Kasman; Hani Bou Reslan; Jed Ross; Nick Van Bruggen; Richard A D Carano; Yu-Ju Gloria Meng; Jo-Anne Hongo; Jean-Philippe Stephan; Masabumi Shibuya; Napoleone Ferrara
Journal:  Cell       Date:  2010-04-02       Impact factor: 41.582

3.  VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy.

Authors:  Renhai Cao; Yuan Xue; Eva-Maria Hedlund; Zhaodong Zhong; Katerina Tritsaris; Barbara Tondelli; Franco Lucchini; Zhenping Zhu; Steen Dissing; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

4.  Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice.

Authors:  Sulochana S Bhandarkar; Marisa Jaconi; Levi E Fried; Michael Y Bonner; Benjamin Lefkove; Baskaran Govindarajan; Betsy N Perry; Ravi Parhar; Jamie Mackelfresh; Allie Sohn; Michael Stouffs; Ulla Knaus; George Yancopoulos; Yvonne Reiss; Andrew V Benest; Hellmut G Augustin; Jack L Arbiser
Journal:  J Clin Invest       Date:  2009-07-13       Impact factor: 14.808

Review 5.  Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance.

Authors:  Yihai Cao; Weide Zhong; Yan Sun
Journal:  Semin Cancer Biol       Date:  2009-05-27       Impact factor: 15.707

6.  Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature.

Authors:  Eva-Maria Hedlund; Kayoko Hosaka; Zhaodong Zhong; Renhai Cao; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-25       Impact factor: 11.205

Review 7.  Positive and negative modulation of angiogenesis by VEGFR1 ligands.

Authors:  Yihai Cao
Journal:  Sci Signal       Date:  2009-02-24       Impact factor: 8.192

Review 8.  FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

Authors:  Christian Fischer; Massimiliano Mazzone; Bart Jonckx; Peter Carmeliet
Journal:  Nat Rev Cancer       Date:  2008-12       Impact factor: 60.716

Review 9.  Tumor angiogenesis and molecular targets for therapy.

Authors:  Yihai Cao
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

Review 10.  Why are tumour blood vessels abnormal and why is it important to know?

Authors:  J A Nagy; S-H Chang; A M Dvorak; H F Dvorak
Journal:  Br J Cancer       Date:  2009-02-24       Impact factor: 7.640

View more
  30 in total

1.  Enhanced antitumor activity and attenuated cardiotoxicity of Epirubicin combined with Paeonol against breast cancer.

Authors:  Jing Wu; Xia Xue; Bin Zhang; Hongmei Cao; Feng Kong; Wen Jiang; Juan Li; Deqing Sun; Ruichen Guo
Journal:  Tumour Biol       Date:  2016-06-07

2.  VEGF-B promotes cancer metastasis through a VEGF-A-independent mechanism and serves as a marker of poor prognosis for cancer patients.

Authors:  Xiaojuan Yang; Yin Zhang; Kayoko Hosaka; Patrik Andersson; Jian Wang; Fredrik Tholander; Ziquan Cao; Hiromasa Morikawa; Jesper Tegnér; Yunlong Yang; Hideki Iwamoto; Sharon Lim; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-19       Impact factor: 11.205

Review 3.  Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC).

Authors:  Mario Scartozzi; Loic Vincent; Marielle Chiron; Stefano Cascinu
Journal:  Target Oncol       Date:  2016-08       Impact factor: 4.493

4.  Inhibition of FoxM1-Mediated DNA Repair by Imipramine Blue Suppresses Breast Cancer Growth and Metastasis.

Authors:  Subapriya Rajamanickam; Subbarayalu Panneerdoss; Aparna Gorthi; Santosh Timilsina; Benjamin Onyeagucha; Dmytro Kovalskyy; Dmitri Ivanov; Martha A Hanes; Ratna K Vadlamudi; Yidong Chen; Alexander J Bishop; Jack L Arbiser; Manjeet K Rao
Journal:  Clin Cancer Res       Date:  2016-02-29       Impact factor: 12.531

5.  Modulation of age-related insulin sensitivity by VEGF-dependent vascular plasticity in adipose tissues.

Authors:  Jennifer Honek; Takahiro Seki; Hideki Iwamoto; Carina Fischer; Jingrong Li; Sharon Lim; Nilesh J Samani; Jingwu Zang; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-30       Impact factor: 11.205

Review 6.  Molecular and cellular underpinnings of normal and abnormal human placental blood flows.

Authors:  Yingchun Li; Ramón A Lorca; Emily J Su
Journal:  J Mol Endocrinol       Date:  2017-11-02       Impact factor: 5.098

7.  Effects of dietary salt levels on monocytic cells and immune responses in healthy human subjects: a longitudinal study.

Authors:  Buqing Yi; Jens Titze; Marina Rykova; Matthias Feuerecker; Galina Vassilieva; Igor Nichiporuk; Gustav Schelling; Boris Morukov; Alexander Choukèr
Journal:  Transl Res       Date:  2014-11-22       Impact factor: 7.012

8.  Angiotensin-(1-7) Suppresses Hepatocellular Carcinoma Growth and Angiogenesis via Complex Interactions of Angiotensin II Type 1 Receptor, Angiotensin II Type 2 Receptor and Mas Receptor.

Authors:  Yanping Liu; Bin Li; Ximing Wang; Guishuang Li; Rui Shang; Jianmin Yang; Jiali Wang; Meng Zhang; Yuguo Chen; Yun Zhang; Cheng Zhang; Panpan Hao
Journal:  Mol Med       Date:  2015-07-27       Impact factor: 6.354

9.  Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy.

Authors:  Yin Zhang; Yunlong Yang; Kayoko Hosaka; Guichun Huang; Jingwu Zang; Fang Chen; Yun Zhang; Nilesh J Samani; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-28       Impact factor: 11.205

10.  Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production.

Authors:  Masaki Nakamura; Yin Zhang; Yunlong Yang; Ceylan Sonmez; Wenyi Zheng; Guichun Huang; Takahiro Seki; Hideki Iwamoto; Bo Ding; Linlin Yin; Theodoros Foukakis; Thomas Hatschek; Xuri Li; Kayoko Hosaka; Jiaping Li; Guohua Yu; Xinsheng Wang; Yizhi Liu; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.